Abstract:
Background: Neuropathic pain is relatively common and occurs in approximately 6–8% of the population.
It is associated with allodynia and hyperalgesia. Thus, non-pharmacological treatments, such as transcranial direct current stimulation (tDCS) may be useful for relieving pain.
Objectives: This study aimed to investigate the antiallodynic effect of tDCS in a mice model of neuropathic pain, and the underlying neurotransmission systems that could drive these effects.
Methods: Male, Swiss mice, weighing 25–35 g, were subjected to partial sciatic nerve ligation (PSNL).
Allodynia was assessed using a Von Frey filament (0.6 g). First, the behavioral time-course of these mice
was assessed after 5, 10, 15 and 20 min of tDCS (0.5 mA). Second, the mice that underwent PSNL were
assigned to either the tDCS (0.5 mA, 15 min) or tDCS sham group, and further assigned to receive either
saline or a drug (i.e., naloxone, yohimbine, a-methyl-p-tyrosine, q-chlorophenylalanine methyl ester, caffeine, 1,3-dipropyl-8-cyclopentylxanthine, AM281, AM630, flumazenil, MK-801, or lidocaine).
Results: The antiallodynic effect of tDCS lasted 2 h and 4 h, after 10 min and 15 or 20 min of treatment,
respectively (P < .001, P < .01, and P < .05, respectively). The antiallodynic effect of tDCS was associated
with all the systems that were analyzed, i.e., the opioidergic (P < .01), adenosinergic (P < .001), serotonergic (P < .01), noradrenergic (P < .001), cannabinoid (P < .001), GABAergic, and glutamatergic (P < .001)
systems. Lidocaine did not reverse the antiallodynic effect of tDCS (P > .05).
Conclusion: The antiallodynic effect of tDCS was associated with different neurotransmitters systems; the
duration of these after-effects depended on the time exposure to tDCS.
